TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
| Current price | $7.97 | 52-week high | $942.48 |
| Prev. close | $8.21 | 52-week low | $6.15 |
| Day low | $7.81 | Volume | 14,700 |
| Day high | $8.40 | Avg. volume | 211,849 |
| 50-day MA | $8.63 | Dividend yield | N/A |
| 200-day MA | $186.62 | Market Cap | 6.64M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Price Returns
| 1-mo | 17.38% |
| 3-mo | -42.50% |
| 6-mo | -91.55% |
| 1-year | -99.14% |
| 3-year | -100.00% |
| 5-year | N/A |
| YTD | -91.55% |
| 2024 | -98.45% |
| 2023 | -98.78% |
| 2022 | -73.50% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...